摘要
病理性近视脉络膜新生血管(PM-CNV)是导致病理性近视患者视力丧失的常见并发症,其发病机制涉及机械牵拉、缺氧和炎症等诸多因素。抗血管内皮生长因子疗法是治疗PM-CNV的有效方法,雷珠单抗、阿柏西普和康柏西普等抗血管内皮生长因子药物经临床试验证实均能改善PM-CNV患者视力,但各有其特点和适用范围。本文综述了PM-CNV药物治疗的最新进展,以期为临床治疗该病提供参考。
Pathological myopic choroidal neovascularization(PM-CNV)is a common complication leading to vision loss in patients with pathological myopia.Its pathogenesis involves various factors,including mechanical traction,hypoxia,and inflammation.Anti-vascular endothelial growth factor therapy has been proven to be effective in the treatment of PM-CNV.Clinical trials have demonstrated that anti-vascular endothelial growth factor drugs,such as ranibizumab,aflibercept,and conbercept,can improve the vision of patients with PM-CNV,each with its characteristics and applicable scope.This article reviews the latest advancements in drug treatment for PM-CNV,aiming to provide valuable reference for the clinical management of this disease.
作者
张宁晖
解孝锋
田庆梅
毕宏生
ZHANG Ninghui;XIE Xiaofeng;TIAN Qingmei;BI Hongsheng(Shandong University of Traditional Chinese Medicine,Jinan250014,Shandong Province,China;Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine,Shandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases,Shandong Academy of Eye Disease Prevention and Therapy,Jinan 250002,Shandong Province,China)
出处
《眼科新进展》
CAS
北大核心
2025年第1期66-70,共5页
Recent Advances in Ophthalmology
基金
国家自然科学基金项目(编号:82305322,82104937)
国家重点研发计划项目(编号:2021YFC2702103,2019YFC1710200)
山东省中医药科技发展项目(编号:M-2022162)
山东省自然科学基金项目(编号:ZR2020QH314)
山东省中西医结合专病防治项目(编号:YXH2019ZXY001)。
关键词
脉络膜新生血管
抗血管内皮生长因子
疗效比较
光学相干断层扫描
choroidal neovascularisation
anti-vascular endothelial growth factor
efficacy comparison
optical coherence tomography
